Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Non-Current Debt (2016 - 2026)

Cytosorbents filings provide 9 years of Non-Current Debt readings, the most recent being $16.7 million for Q4 2025.

  • On a quarterly basis, Non-Current Debt rose 19.08% to $16.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $16.7 million, a 19.08% increase, with the full-year FY2025 number at $16.7 million, up 19.08% from a year prior.
  • Non-Current Debt hit $16.7 million in Q4 2025 for Cytosorbents, up from $14.6 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $16.7 million in Q4 2025 to a low of $1.9 million in Q1 2024.
  • Median Non-Current Debt over the past 4 years was $13.7 million (2024), compared with a mean of $10.0 million.
  • Biggest five-year swings in Non-Current Debt: tumbled 49.14% in 2023 and later soared 635.61% in 2025.
  • Cytosorbents' Non-Current Debt stood at $5.0 million in 2022, then tumbled by 49.14% to $2.5 million in 2023, then soared by 450.4% to $14.0 million in 2024, then rose by 19.08% to $16.7 million in 2025.
  • The last three reported values for Non-Current Debt were $16.7 million (Q4 2025), $14.6 million (Q3 2025), and $14.4 million (Q2 2025) per Business Quant data.